<DOC>
	<DOCNO>NCT00002144</DOCNO>
	<brief_summary>PRIMARY : To evaluate clinical activity foscarnet cream index lesion mucocutaneous herpes simplex virus ( HSV ) infection immunocompromised patient previously unresponsive acyclovir treatment . SECONDARY : To evaluate clinical activity virologic activity foscarnet cream treat lesion patient population . To evaluate local tolerance side effect treatment foscarnet cream patient population .</brief_summary>
	<brief_title>The Pilot Study Foscarnet Cream Treatment Mucocutaneous Herpes Simplex Virus Infections Immunocompromised Patients Unresponsive Acyclovir Treatment</brief_title>
	<detailed_description>Patients receive topical application one percent foscarnet cream five time daily 6 week ; show evidence epithelialization index lesion 3 week remove study offer intravenous foscarnet . Patients show good response topical foscarnet cream end 6 week may continue receive treatment discretion investigator .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Ganciclovir ( provide drug administer least 14 day prior study entry , HSV isolate exhibit resistance acyclovir ) . Other medication consider necessary patient 's welfare , discretion investigator . Patients must : HIV infection AIDS . Mucocutaneous HSV infection least one clinically evaluable lesion . Prior acyclovir without clinical benefit . Life expectancy least 3 month . Consent parent guardian le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity study drug . Any medical , psychiatric , condition would preclude study compliance . Incapable self administration medication presence care provider administer medication . Concurrent Medication : Excluded : Intravenous foscarnet current episode HSV . Acyclovir , interferon , investigational drug might antiHSV activity ( e.g. , 256U87 , HPMPC , BVDaraU , trifluridine ) . Patients follow prior condition exclude : Previous participation study . Prior Medication : Excluded : Intravenous foscarnet within 2 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Herpes Simplex</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>